Immunotherapy combo trial aims to boost survival in head and neck cancer

NCT ID NCT07362979

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiotherapy, can improve outcomes for people with locally advanced nasopharyngeal cancer. About 243 participants will be randomly assigned to one of three treatment combinations. The goal is to find which combination offers the best chance of preventing the cancer from returning or spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab (an immunotherapy drug) combined with platinum-based chemotherapy (gemcitabine, cisplatin, or nab-paclitaxel)
What this could lead to: If successful, this could identify a more effective treatment combination for advanced nasopharyngeal cancer, potentially improving survival rates.
What could go wrong: This is an early phase II trial with a moderate size (243 participants). Results may not confirm benefit, and side effects from combining immunotherapy with chemotherapy can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCINOMA (NPC)

Contacts and locations

Locations

Affiliated Hospital of Guangdong Medical University
RECRUITING

Zhanjiang, Guangdong, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen
RECRUITING

Shenzhen, Guangdong, China
Dongguan People's Hospital
RECRUITING

Dongguan, Guangdong, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.